ATRA
Atara Biotherapeutics
Stock NASDAQ – Stock Market Prices, News & Analysis
Atara Biotherapeutics Inc is committed to developing treatments for autoimmune diseases and cancers using T cell technology.
Atara Biotherapeutics
ATRA
Atara Biotherapeutics Inc is committed to developing treatments for autoimmune diseases and cancers using T cell technology.
Price history of Atara Biotherapeutics
Price history of Atara Biotherapeutics
Performance & Momentum
Atara Biotherapeutics Q3 Losses Slash Stock by 50%
Atara Biotherapeutics (NASDAQ: ATRA) reported a $4.3 million loss in Q3 2025, continuing to post negative financial results. The stock plunged over 50% on Monday, January 12, following the announcement. However, the company remains a key player in the rapidly growing market for therapies targeting Epstein-Barr virus (EBV), which is linked to several serious diseases, including certain cancers and autoimmune disorders.
Strategic Analysis
Atara Biotherapeutics • 2026
Atara Biotherapeutics positions itself as a niche player in the healthcare sector by developing innovative T-cell therapies to treat autoimmune diseases and certain cancers, a field with high scientific potential but significant clinical failure risks.
Strengths
- Advanced expertise in immuno-oncology and T-cell technology
- Focus on under-treated indications with a strong medical need
- Potential for technological breakthroughs in a dynamic sector
Weaknesses
- Significant historical financial performance decline over several years
- Lack of recent significant news to support valuation
Momentum
The current momentum is very weak with past performance declining sharply, reflecting ongoing operational and financial challenges. The absence of immediate catalysts calls for caution, even though the valuation already seems to reflect these difficulties.
Recent News
Atara Biotherapeutics
Atara Biotherapeutics Q3 Results Mixed Despite EBV Market Growth
2 months agoAtara Biotherapeutics, listed on NASDAQ under ticker ATRA, reported a $4.3 million loss in Q3 2025, reflecting ongoing operational challenges. However, the company benefits from a favorable backdrop with rapid growth in the Epstein-Barr virus (EBV) targeted therapy market, where Atara is a key player. This momentum, driven by the expansion of immunotherapy treatments, could support long-term valuation potential despite the disappointing quarterly performance.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
